View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Half-year statement on Nexans liquidity contract - January 1st to June...

Half-year statement on Nexans liquidity contract - January 1st to June 30th, 2025    Half-year liquidity contract statement for Nexans _PRESS RELEASE_ Paris, July 2nd, 2025 – Pursuant to the liquidity contract granted by NEXANS to NATIXIS ODDO BHF, the following assets appeared on the dedicated liquidity account as of June 30th, 2025: 49,612 sharesEUR 3,006,649.02 in cashNumber of purchase transactions executed over the semester: 6,346Number of sales transactions executed over the semester: 5,737Volume traded over the semester for purchase: 944,611 shares for EUR 91,406,765.50Volume tra...

 PRESS RELEASE

Bilan semestriel du contrat de liquidité - Du 1er janvier au 30 juin 2...

Bilan semestriel du contrat de liquidité - Du 1er janvier au 30 juin 2025    BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE DE LA SOCIETE NEXANS _COMMUNIQUÉ DE PRESSE_ Paris, le 2 juillet 2025 – Au titre du contrat de liquidité confié par NEXANS SA à NATIXIS ODDO BHF, les ressources suivantes figuraient au compte de liquidité dédié, à la date du 30 juin 2025 : 49 612 titres3 006 649,02 euros en espèces Nombre de transactions exécutées sur le semestre à l'achat : 6 346Nombre de transactions exécutées sur le semestre à la vente : 5 737Volume échangé sur le semestre à l'achat : 944 611 titres po...

 PRESS RELEASE

Information on share capital and voting rights - June 2025

Information on share capital and voting rights - June 2025 Information on share capital and voting rights June 2025 Statement made in accordance with article L. 233-8 II of the French commercial Code and articles 221-1 2 ° f) and 223-16 of the AMF Regulations. July 1st, 2025 Statement made by:         Nexans S.A.Registered office : 4 Allée de l’Arche - 92400 CourbevoieRCS Nanterre 393 525 852Regulated market of Euronext Paris (Compartment A) DateTotal number of sharesTotal number of voting rightsTheorical (1)Exercisable (2)June 30th, 202543,753,38043,753,38043,745,871 (1)   Calculated ba...

 PRESS RELEASE

Information mensuelle relative au nombre d'actions et de droits de vot...

Information mensuelle relative au nombre d'actions et de droits de vote - Juin 2025 Information mensuelle relative au nombre d’actions et de droits de voteJuin 2025 Déclaration faite en application de l'article L. 233-8 II du code de commerce et des articles 221-1 2° f) et 223-16 du règlement général de l’AMF. Le 1er juillet 2025 Société déclarante : Nexans S.A.Siège social : 4 Allée de l’Arche – 92400 CourbevoieRCS Nanterre 393 525 852Marché réglementé d’Euronext Paris (Compartiment A) DateNombre d’actions composant le capitalNombre total de droits de voteThéoriques (1)Exerçables (2)30...

Valneva SE: 1 director

A director at Valneva SE bought 10,000 shares at 2.431EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

Felix Fischer ... (+6)
  • Felix Fischer
  • Haidje Rustau
  • Jayanth Kandalam
  • Si Yong Ng
  • Tanvi Arora
  • Trung Nguyen

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Victoria, Vallourec, Omnia Technologies, Paprec Group, La Doria, Softbank Group, Maxeda, Mahle, Bombardier, Flora Food Group (formerly Upfield), Nexans, Assemblin, Air Baltic, Virgin Media O2, Nokia

 PRESS RELEASE

Nexans completes the sale of Lynxeo to Latour Capital

Nexans completes the sale of Lynxeo to Latour Capital Paris, June 30th, 2025 – Nexans announces today the completion of the sale of Lynxeo, its industrial cable division, to Latour Capital, a France-based private equity fund, for an Enterprise Value of €525 million. This transaction represents a key milestone in Nexans' strategy to refocus on its core electrification business and establish itself as a pure player in electrification.  Christopher Guérin, Chief Executive Officer of Nexans said: “The closing of the transaction marks a pivotal milestone in our electrification journey. It will ...

 PRESS RELEASE

Nexans finalise la cession de Lynxeo à Latour Capital

Nexans finalise la cession de Lynxeo à Latour Capital Paris, le 30 juin, 2025 – Nexans annonce aujourd’hui la finalisation de la cession de Lynxeo, sa division de câbles industriels, à Latour Capital, un fond de capital-investissement basé en France, pour une valeur d’entreprise de 525 millions d’euros. Cette transaction constitue une étape majeure dans la stratégie de Nexans visant à se recentrer sur son cœur de métier, l’électrification, et à devenir un pure player du secteur.  Christopher Guérin, Directeur général de Nexans, a déclaré: “La finalisation de cette transaction marque une ét...

Olfa Taamallah ... (+3)
  • Olfa Taamallah
  • Roy Külter
  • Yan Derocles
Martial Descoutures
  • Martial Descoutures
Olfa Taamallah ... (+3)
  • Olfa Taamallah
  • Roy Külter
  • Yan Derocles
Martial Descoutures
  • Martial Descoutures
Felix Fischer
  • Felix Fischer

Lucror Analytics - Convertibles Brief

In today's Convertibles Brief publication we comment on developments of the following high yield issuers: AMS Osram

 PRESS RELEASE

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreeme...

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus Saint-Herblain, France, June 26, 2025 – , (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the world’s largest influenza vaccine companies, for the marketing and distribution of Valneva’s three proprietary vaccines in Germany. Under the agreed terms, CSL Seqirus will start commercializing Valneva’s single-dose chikungunya vaccine IXCHIQ® from July 2025, and Valneva’s Japanese Encephalitis vaccine IXIARO® and ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch